Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in JapanZacks Investment Research • 10/16/25
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific RegionPRNewsWire • 10/15/25
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a RowPRNewsWire • 10/08/25
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation OfficerPRNewsWire • 08/19/25
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial GuidancePRNewsWire • 08/07/25
Viatris Announces Appointment of David Simmons to the Company's Board of DirectorsPRNewsWire • 08/05/25
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?Zacks Investment Research • 08/04/25
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 ConferencePRNewsWire • 08/01/25
10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payoutsMarket Watch • 07/22/25